Transcriptomics-driven exploration of genetic variation and peptide discovery in the sea anemones Anthopleura midori and Actinia equina

利用转录组学方法探索海葵 Anthopleura midori 和 Actinia equina 的遗传变异和肽发现

阅读:1

Abstract

Exploring sea anemone polypeptides enables us to understand the evolutionary history and ecological adaptation strategies of species at the microscopic level. More importantly, it aims to provide a solid theoretical foundation for drug development and biodiversity conservation research. Through systematic research, we discovered a total of 51 toxin sequences in species Anthopleura midori and Acyinia equina. The toxin sequences between the two species exhibited significant differences, with notable diversity observed among individuals. In terms of genetic diversity, species Anthopleura midori primarily exhibits variations due to single nucleotide polymorphisms (SNPs), whereas species Actinia equina shows frequent insertion and deletion events. In transcription factor analysis, both species Anthopleura midori and Actinia equina share common transcription factors TEA (TEA Domain Transcription Factor), SPL(Squamosa Promoter Binding Protein-like), and bHLH (Basic Helix-Loop-Helix). Notably. Notably, bHLH is highly expressed in Actinia equina, which may give it advantages in muscle and nervous system development. On the other hand, Anthopleura midori may rely on other transcription factors. Furthermore, by employing transcriptomics and mass spectrometry techniques, two new gene families were successfully identified, and five structurally novel cyclic peptides were predicted. Kinetic simulations further confirmed that the peptide segment B3a-c29555_c4_g4 binds primarily through hydrogen bonds and hydrophobic interactions with the Cav3.1 (PDB ID:6 KZO) protein, and this peptide has the potential to act as a channel modulator for Cav3.1. Overall, this research not only deepens our understanding of the genetic basis of toxin diversity but also highlights the great potential of these toxins in the development of novel drugs.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。